Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
Earnings Data
Report Date
May 05, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-2.17Last Year’s EPS
-1.42Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 10, 2025
|% Change Since: -7.48%
|Next Earnings Date:May 05, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook for BioNTech. While there are significant advancements in their oncology pipeline and strategic acquisitions like Biotheus, challenges remain with declining COVID-19 vaccine revenues and ongoing legal costs. Financial losses for 2024 also highlight some operational difficulties. The sentiment is balanced between optimism for future growth and caution due to current financial and operational challenges.Company Guidance
During the BioNTech fourth quarter and full-year 2024 earnings call, the company provided guidance on several key metrics and strategic priorities for 2025. BioNTech expects total revenues to range between EUR 1.7 billion and EUR 2.2 billion, assuming stable vaccination rates and market share for COVID-19 vaccines, while anticipating some inventory write-downs and charges. Research and development (R&D) expenses are projected to be between EUR 2.6 billion and EUR 2.8 billion, driven by increased investment in late-stage programs such as BNT327 and mRNA cancer immunotherapies. Selling, general, and administrative (SG&A) expenses are expected to rise to between EUR 650 million and EUR 750 million, reflecting the company's commercial expansion in oncology. Additionally, capital expenditures are expected to reach EUR 250 million to EUR 350 million. The call emphasized the strategic focus on two pan-tumor programs, BNT327 and mRNA cancer immunotherapies, with several clinical and regulatory milestones anticipated throughout the year, including data updates across various oncology trials and potential regulatory filings.Oncology Pipeline Expansion
BioNTech has significantly increased the number of Phase 2 and 3 trials, especially for their mRNA cancer immunotherapies and BNT327. This expansion aligns with their long-term strategy to focus on high-priority programs like BNT327 and personalized mRNA cancer immunotherapies.
BNT327 Clinical Development
BioNTech initiated multiple trials for BNT327, a PD-L1/VEGF bispecific antibody, in small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer. The company also acquired Biotheus to enhance global capabilities for BNT327 development.
mRNA Cancer Immunotherapy Progress
Significant progress was made with the FixVac and iNeST platforms. FixVac candidate BNT111 met the primary endpoint in a Phase 2 trial for melanoma. The iNeST platform showed promising immune responses in Phase 1 trials, leading to ongoing Phase 2 trials in colorectal cancer, pancreatic cancer, and bladder cancer.
Financial Performance and Guidance
BioNTech reported EUR2.8 billion in revenue for 2024, meeting the midpoint of their guidance. They maintain a strong cash position of EUR17.4 billion. The 2025 revenue guidance is set between EUR1.7 billion and EUR2.2 billion.
Biotheus Acquisition
BioNTech completed the acquisition of Biotheus to secure global control over BNT327 and expand their immunotherapy capabilities, especially in China.
---
BNTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BNTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 10, 2025 | $108.78 | $105.35 | -3.15% |
| Nov 04, 2024 | $111.48 | $108.97 | -2.25% |
| Aug 05, 2024 | $82.01 | $78.36 | -4.45% |
| May 06, 2024 | $92.72 | $93.35 | +0.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioNTech SE (BNTX) report earnings?
BioNTech SE (BNTX) is schdueled to report earning on May 05, 2025, TBA Not Confirmed.
What is BioNTech SE (BNTX) earnings time?
BioNTech SE (BNTX) earnings time is at May 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BNTX EPS forecast?
BNTX EPS forecast for the fiscal quarter 2025 (Q1) is -2.17.
---
